|
WO2021079302A1
|
|
Pharmaceutical combination of prmt5 inhibitors
|
|
WO2021064700A1
|
|
Event status apparatuses and related devices, systems, and methods
|
|
WO2021048779A2
|
|
Modified dosing of vegf inhibitors for ophthalmic use
|
|
WO2021014365A1
|
|
Macrocyclic compounds as sting agonists and methods and uses thereof
|
|
US2021009606A1
|
|
Process for Preparation of Intermediates Used for the Synthesis of HIV Integrase Inhibitor
|
|
WO2020250123A1
|
|
Prmt5 inhibitors
|
|
WO2020240451A1
|
|
In-situ gelling nanoemulsion of brinzolamide
|
|
WO2020234742A1
|
|
Granulocyte colony stimulating factor purification
|
|
WO2020194160A1
|
|
Macrocyclic compounds as sting agonists
|
|
US2020262788A1
|
|
Process for preparation of molindone
|
|
WO2020141419A2
|
|
Novel salts and polymorphic form of bempedoic acid
|
|
WO2020084389A1
|
|
Ribociclib intermediate and process for preparation thereof
|
|
EP3813791A2
|
|
Stable lyophilized dosage form of protein
|
|
WO2019186410A1
|
|
Solid forms of elafibranor and processes thereof
|
|
WO2019130277A1
|
|
Pharmaceutical formulations of azilsartan medoxomil
|
|
AU2018385664A1
|
|
Substituted bicyclic heterocyclic compounds as PRMT5 inhibitors
|
|
WO2019058271A1
|
|
Process for the preparation of eluxadoline
|
|
WO2018225043A1
|
|
Solid state forms of an apoptosis-inducing agent and processes thereof
|
|
WO2018211479A1
|
|
Stabilized compositions of angiotensin ii inhibitors and neutral endopeptidase inhibitors and process for preparation thereof
|
|
WO2018198086A1
|
|
Process for the preparation of elagolix and pharmaceutically acceptable salts thereof
|
